Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens More: Amgen reveals new combination data for KRAS inhibitor Source: News
read moreThe new consumer healthcare company will be based at a newly built campus in Weybridge More: GSK plans UK headquarters for new consumer healthcare company Source: News
read moreAZD7442 cut the risk of severe COVID-19 and death by 50% in outpatients More: AZ’s long-acting antibody combo shows benefit in COVID-19 trial Source: News
read moreEyes itching from allergies? Ocular’s Dextenza wins FDA approval as first monthly implant aliu Tue, 10/12/2021 – 05:51 More: Eyes itching from allergies? Ocular's Dextenza wins FDA approval as first monthly implant Source: fierce
read moreSupernus strikes $400M+ Adamas buyout as its top drug heads toward the patent cliff esagonowsky Mon, 10/11/2021 – 15:06 More: Supernus strikes 0M+ Adamas buyout as its top drug heads toward the patent cliff Source: fierce
read morePacira boosts nonopioid pain portfolio via $450M Flexion buy, with more CVR payments to come aliu Mon, 10/11/2021 – 11:27 More: Pacira boosts nonopioid pain portfolio via 0M Flexion buy, with more CVR payments to come Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals